Percutaneous Pancreatic Biopsy Guidelines

Patient Selection and Indications

The European Society for Medical Oncology recommends that percutaneous pancreatic biopsies should be restricted to cases where histological confirmation is required for palliative therapy planning or clinical trial enrollment, and should generally be avoided in potentially resectable lesions 3, 2
The American Society of Clinical Oncology states that tissue diagnosis is mandatory in unresectable cases or when neoadjuvant therapy is planned, but not required before surgery with radical intent 1, 4

The American College of Gastroenterology recommends thoroughly assessing coagulation status, as INR >1.5 increases bleeding risk from 1.1% to 7.1% 5
The National Comprehensive Cancer Network advises checking platelet count, as thrombocytopenia (<150×10⁹/L) increases bleeding risk from 1.6% to 2.9% 5

The European Society for Medical Oncology suggests considering the needle trajectory carefully to avoid traversing major vessels and the gastrointestinal tract 3, 2

The American Society of Clinical Oncology recommends that failure to obtain histological confirmation does not exclude malignancy and should not delay appropriate surgical treatment in highly suspicious cases 3, 2
The National Comprehensive Cancer Network states that for metastatic lesions, percutaneous biopsy under ultrasound or CT guidance is appropriate 1

The European Society for Medical Oncology warns that the risk of tumor seeding along the needle track or within the peritoneum is a significant concern, particularly for potentially resectable tumors 3, 2
The American Society of Clinical Oncology advises that false negative results can occur, and a negative biopsy should be confirmed by at least one repeat biopsy before excluding malignancy 6